ciprofloxacin has been researched along with flucytosine in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (35.71) | 29.6817 |
2010's | 7 (50.00) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Chovatia, PT; Parekh, HH; Pathak, RB | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Mishra, NN; Prabhakar, YS; Saquib, M; Sharma, S; Shaw, AK; Shukla, PK; Srivastava, R; Verma, S | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Alexandrova, LA; Avdanina, DA; Boykova, YV; Efimenko, TA; Efremenkova, OV; Glukhova, AA; Jasko, MV; Karpenko, IL; Kochetkov, SN; Kolonitskaya, DP; Kost, NV; Negrya, SD; Nuraeva, GK; Shevchenko, OV; Solodinin, AP; Solyev, PN; Volkov, IA; Zhgun, AA | 1 |
Petrou, MA; Rogers, TR | 1 |
Jandhyala, D; Sohail, MR; Stahr, DC; Tan, EM | 1 |
1 review(s) available for ciprofloxacin and flucytosine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for ciprofloxacin and flucytosine
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
Topics: Anti-Infective Agents; Bacteria; Carbohydrates; Catalytic Domain; Cell Line; Chemistry Techniques, Synthetic; Click Chemistry; Drug Design; Fungi; Microbial Sensitivity Tests; Models, Molecular; Penicillin-Binding Proteins; Triazoles | 2014 |
Discovery of novel N
Topics: A549 Cells; Animals; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Cytidine; Drug Discovery; Fungi; Humans; Microbial Sensitivity Tests | 2021 |
In-vitro activity of antifungal agents in combination with four quinolones.
Topics: 4-Quinolones; Amphotericin B; Anti-Infective Agents; Antifungal Agents; Candida; Candida albicans; Ciprofloxacin; Drug Combinations; Enoxacin; Flucytosine; Mepartricin; Nalidixic Acid; Naphthyridines; Norfloxacin; Quinolines; Saccharomyces cerevisiae | 1988 |
Disseminated
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Cryptococcosis; Cryptococcus neoformans; Extracorporeal Membrane Oxygenation; Fluconazole; Flucytosine; Heart-Assist Devices; Humans; Immunocompetence; Intra-Aortic Balloon Pumping; Male; Middle Aged; Shock, Septic; ST Elevation Myocardial Infarction | 2019 |